Abstract
Background: Little is known about the therapeutic role of intravenous interferon-beta in chronic hepatitis C patients unresponsive to a previous treatment with interferon-alpha. Methods: Two hundred interferon alpha non- responders were randomized to receive either intravenous recombinant interferon-beta or interferon-alpha-2b and ribavirin for 12 weeks. The responders in both groups were followed up for a further 48 weeks. Results: At week 12 a biochemical and virologic response was documented in 42% of the patients treated with interferon-beta and in 22% of the patients treated with combination therapy. A sustained response was observed in 21% of the patients treated with interferon-beta and in 13% of those treated with combination therapy, with similar differences on intention-to-treat analysis. Conclusions: Short-term treatment with intravenous interferon-beta seems to offer a chance for sustained response in a subset of interferon-alpha non- responders. The role of long-term therapy in these patients still remains to be explored.
| Original language | English |
|---|---|
| Pages (from-to) | 928-933 |
| Number of pages | 6 |
| Journal | Scandinavian Journal of Gastroenterology |
| Volume | 34 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - 1999 |
Fingerprint
Keywords
- Chronic hepatitis C
- Interferon-alpha
- Interferon-beta
- Ribavirin
ASJC Scopus subject areas
- Gastroenterology
Cite this
Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha. / Barbaro, G.; Di Lorenzo, G.; Soldini, M.; Gianeaspro, G.; Pellicelli, A.; Grisorio, B.; Barbarini, G.; De Rosa, F.; Cadario, F.; Capelli, D.; Filice, G.; Paiano, A.; Belloni, G.; Ferrari, L.; Gualandi, G.; Poltronieri, I.; Barelli, A.; Rocchetto, P.; Del Poggio, P.; Bellomo, G.; Calleri, G.; Cariti, G.; Fruttaldo, L.; Mongiò, F.; Rizzo, G.; Annese, M.; Scotto, G.; Bacca, D.; Francavilla, R.
In: Scandinavian Journal of Gastroenterology, Vol. 34, No. 9, 1999, p. 928-933.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha
AU - Barbaro, G.
AU - Di Lorenzo, G.
AU - Soldini, M.
AU - Gianeaspro, G.
AU - Pellicelli, A.
AU - Grisorio, B.
AU - Barbarini, G.
AU - De Rosa, F.
AU - Cadario, F.
AU - Capelli, D.
AU - Filice, G.
AU - Paiano, A.
AU - Belloni, G.
AU - Ferrari, L.
AU - Gualandi, G.
AU - Poltronieri, I.
AU - Barelli, A.
AU - Rocchetto, P.
AU - Del Poggio, P.
AU - Bellomo, G.
AU - Calleri, G.
AU - Cariti, G.
AU - Fruttaldo, L.
AU - Mongiò, F.
AU - Rizzo, G.
AU - Annese, M.
AU - Scotto, G.
AU - Bacca, D.
AU - Francavilla, R.
PY - 1999
Y1 - 1999
N2 - Background: Little is known about the therapeutic role of intravenous interferon-beta in chronic hepatitis C patients unresponsive to a previous treatment with interferon-alpha. Methods: Two hundred interferon alpha non- responders were randomized to receive either intravenous recombinant interferon-beta or interferon-alpha-2b and ribavirin for 12 weeks. The responders in both groups were followed up for a further 48 weeks. Results: At week 12 a biochemical and virologic response was documented in 42% of the patients treated with interferon-beta and in 22% of the patients treated with combination therapy. A sustained response was observed in 21% of the patients treated with interferon-beta and in 13% of those treated with combination therapy, with similar differences on intention-to-treat analysis. Conclusions: Short-term treatment with intravenous interferon-beta seems to offer a chance for sustained response in a subset of interferon-alpha non- responders. The role of long-term therapy in these patients still remains to be explored.
AB - Background: Little is known about the therapeutic role of intravenous interferon-beta in chronic hepatitis C patients unresponsive to a previous treatment with interferon-alpha. Methods: Two hundred interferon alpha non- responders were randomized to receive either intravenous recombinant interferon-beta or interferon-alpha-2b and ribavirin for 12 weeks. The responders in both groups were followed up for a further 48 weeks. Results: At week 12 a biochemical and virologic response was documented in 42% of the patients treated with interferon-beta and in 22% of the patients treated with combination therapy. A sustained response was observed in 21% of the patients treated with interferon-beta and in 13% of those treated with combination therapy, with similar differences on intention-to-treat analysis. Conclusions: Short-term treatment with intravenous interferon-beta seems to offer a chance for sustained response in a subset of interferon-alpha non- responders. The role of long-term therapy in these patients still remains to be explored.
KW - Chronic hepatitis C
KW - Interferon-alpha
KW - Interferon-beta
KW - Ribavirin
UR - http://www.scopus.com/inward/record.url?scp=0032888775&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032888775&partnerID=8YFLogxK
U2 - 10.1080/003655299750025426
DO - 10.1080/003655299750025426
M3 - Article
C2 - 10522614
AN - SCOPUS:0032888775
VL - 34
SP - 928
EP - 933
JO - Scandinavian Journal of Gastroenterology
JF - Scandinavian Journal of Gastroenterology
SN - 0036-5521
IS - 9
ER -